University of Miami will invest $30 million to to fuel neuroscience and aging research
October 17, 2024 11:35 ET
|
University of Miami
CORAL GABLES, Fla., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Demonstrating its commitment to excellence as a member of the Association of American Universities and number one in the state for National...
Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery of GLP-1 Incretin Triagonist
October 17, 2024 08:00 ET
|
Rani Therapeutics, LLC
-Transenteric delivery of incretin triagonist GLP-1, GIP, glucagon receptors mimicking the RaniPill route of administration elicits rapid weight loss and bioavailability comparable to subcutaneous...
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months
October 17, 2024 07:50 ET
|
ZyVersa Therapeutics
It is anticipated that Inflammasome ASC Inhibitor IC 100 will control chronic inflammation of obesity, attenuate comorbidities, and enhance weight loss.
Are Obesity and Alzheimer’s Linked? KGI Professor Awarded Grant to Find Out
October 16, 2024 13:21 ET
|
Keck Graduate Institute
Claremont, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- One of the most devastating diseases to affect the brain could potentially be linked to the liver, and Associate Professor of Biochemistry and...
VedTechBio® Launches RxAgentAI™ – an Artificial Intelligence and Machine Learning Platform, catering to the decision making and strategic needs of stakeholders in the life sciences industry AND VedTechBio® Announces a Drug Discovery Collaboration with RenaissThera®
October 16, 2024 06:00 ET
|
VedTechBio
VedTechBio launches RxAgentAI – an AI and ML Platform. VedTechBio announces a Drug Discovery Collaboration with RenaissThera.
Neurogastrx Announces Positive Proof-of-Concept Data for Investigational Drug NG101 in Reducing Nausea and Vomiting Associated with the Administration of GLP-1 Agonist Medication
October 16, 2024 05:30 ET
|
Neurogastrx
Neurogastrx Announces Positive POC Data for Investigational Drug NG101 in Reducing Nausea & Vomiting Associated with GLP-1 Agonists
ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors
October 15, 2024 07:50 ET
|
ZyVersa Therapeutics
ZyVersa discusses trend toward add-on therapy for obesity to address metabolic complications and the role of inflammasome inhibitors on Big Biz Show.
Forbion raises in excess of €2 billion for two new funds
October 15, 2024 01:00 ET
|
Forbion
Forbion’s largest fundraising to date with Forbion’s Growth Opportunities Fund III raising €1.2 billion & Forbion Ventures Fund VII raising €890 million
ICPO Foundation geht eine Partnerschaft mit der International Atomic Energy Agency (IAEA) ein
October 10, 2024 04:15 ET
|
ICPO Foundation
Die Parteien kooperieren weltweit im Bereich der therapeutischen klinischen Anwendungen der Nuklearmedizin in der Onkologie. 10. Oktober 2024 – Wiesbaden, Deutschland. Heute kündigte die...
ICPO Foundation partners with the International Atomic Energy Agency (IAEA)
October 10, 2024 04:15 ET
|
ICPO Foundation
The parties cooperate in the area of therapeutic clinical applications of nuclear medicine in oncology worldwide. October 10, 2024 – Wiesbaden, Germany. Today, the International Centers for...